InvestorsHub Logo
Followers 215
Posts 22621
Boards Moderated 0
Alias Born 10/22/2006

Re: None

Thursday, 01/28/2021 3:55:03 PM

Thursday, January 28, 2021 3:55:03 PM

Post# of 499
Not new news but I like the smart reporting style:
Omeros's Biologics License Application for Blood Vessel Damage Treatment Candidate Accepted for Priority Review by FDA

1/19/21, 8:06 AM
10:06 AM EST, 01/19/2021 (MT Newswires) -- Omeros (OMER) said Tuesday its biologics license application for narsoplimab, a potential treatment for transplant-associated thrombotic microangiopathy, has been accepted for priority review by the US Food and Drug Administration.

Thrombotic microangiopathy is characterized by a pattern of damage in the small blood vessels.

The FDA has set the Prescription Drug User Fee Act action date on July 17.



Emil Nolde

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent OMER News